CAS: 1462470-54-7; (S)-2-(2-(2-((3-(((3,4-Dimethoxybicyclo[4.2.0]Octa-1,3,5-Trien-7-yl)Methyl)(Methyl)Amino)Propyl)Amino)Ethyl)-4,5-Dimethoxyphenyl)Acetic Acid (Ivabradine Impurity)
该化合物是一种治疗慢性心脏病和心肌炎的药物,其特征明确的结构和稳定性确保了HPLC,LC-MS和其他分析技术的可靠性能;杂质提供了综合文件,包括色谱数据和光谱剖面图,以支持方法验证和监管合规;其可用性有助于在药物研发和制造期间进行精确的不纯度特征分析,从而确保伊瓦布拉德配方的安全性和有效性.
- 英文名称(S)-2-(2-(2-((3-(((3,4-Dimethoxybicyclo[4.2.0]Octa-1,3,5-Trien-7-yl)Methyl)(Methyl)Amino)Propyl)Amino)Ethyl)-4,5-Dimethoxyphenyl)Acetic Acid (Ivabradine Impurity)
- 中文名称(S)-2-(2-(2-((3-(((3,4-二甲氧基双环[4.2.0]八-1,3,5-三烯-7-基)甲基)(甲基)氨基)丙基)氨基)乙基)-4,5-二甲氧苯基)乙酸 (伊伐布雷定杂质)
- IUPAC名称(S)-2-(2-(2-((3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)amino)ethyl)-4,5-dimethoxyphenyl)acetic acid
- 其它别名Vabradine Impurity 1; {2-[2-({3-[{[(7S)-3,4-Dimethoxybicyclo[4.2.0]Octa-4,3,5-Trien-7-Yl]Methyl}(Methyl)-Amino]Propyl}Amino)Ethyl]-4,5-Dimethoxyphenyl}Acetic Acid; (S)-3-(3-(((3,4-Dimethoxybicyclo[4.2.0]Octa-1(6),2,4-Trien-7-yl)Methyl)(Methyl)Amino)Propyl)-7,8-Dimethoxy-1H-Benzo[d]Azepin-2(3H)-One Hydrochloride; Benzeneacetic Acid, 2-[2-[[3-[[[(7S)-3,4-Dimethoxybicyclo[4.2.0]Octa-1,3,5-Trien-7-Yl]Methyl]Methylamino]Propyl]Amino]Ethyl]-4,5-Dimethoxy-; (S)-2-(2-(2-((3-(((3,4-Dimethoxybicyclo[4.2.0]Octa-1(6),2,4-Trien-7-yl)Methyl)(Methyl)Amino)Propyl)Amino)Ethyl)-4,5-Dimethoxyphenyl)Acetic Acid; (S)-2-(2-(2-((3-(((3,4-Dimethoxybicyclo[4.2.0]Octa-1,3,5-Trien-7-yl)Methyl)(Methyl)Amino)Propyl)Amino)Ethyl)-4,5-Dimethoxyphenyl)Acetic Acid (Ivabradine Impurity)
- CAS编号1462470-54-7
- FDA UNII编号:QYE4AE4479
- 分子式:C27H38N2O6分子量:486.61
- 产品CID: 696218
- 产品分类有机原料→分子砌块→芳环类化合物→苯类化合物
相似化合物
304464-98-0 304462-60-0 167072-91-5物理性质
MSDS等安全信息
上下游产品
[2-(2-aminoethyl)-4,5-dimethoxyphenyl]acetonitrile {2-[2-({3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]°Cta-1,3,5-trien-7-yl]methyl}(methyl)-amino]propyl}amino)ethyl]-4,5-dimethoxyphenyl}acetonitrile 2-(3,4-dimethoxyphenyl)-ethylamine N-[2-(3,4-dimethoxyphenyl)ethyl]-2,2,2-trifluoroacetamideivabradine合成工艺路线路线简述
📜盐酸伊伐布雷定置于水,Sodium Hydroxide体系中,用 乙腈 用作溶剂,化学反应 1.0H,反应生成伊伐布雷定杂质
参考文献:通过lc-Hr-Ms / Ms表征伊伐布雷定的降解产物:在hcl和h2So4酸水解中表现出不同降解行为的典型案例.
标题:通过lc-Hr-Ms / Ms表征伊伐布雷定的降解产物:在hcl和h2So4酸水解中表现出不同降解行为的典型案例.
摘要:建立了经过验证的稳定性指示HPLC方法,并按照ich指南对强心药ivabradine进行了全面的压力测试.伊伐布雷定经历了酸性,碱性和中性水解,氧化,光解和热应力条件,并通过lc-Pda和lc-Hr-Ms / Ms研究了所得的降解产物.发现该药物在酸和碱水解中降解.在phenomenex Luna C18(250 X 4.6 Mm,5.0微米)色谱柱上开发了一种高效且选择性的稳定性测定方法,使用甲酸铵(10 Mm,Ph 3.0)和乙腈作为流动相,在30摄氏度下以梯度洗脱模式进行.流速为0.7Ml / Min,检测波长为286Nm.通过lc-Hr-Ms / Ms与准确的质量测量相结合,鉴定并鉴定了总共五种降解产物(i-1至i-5).该药物在hcl和h2So4水解条件下表现出不同的降解行为.这是一个独特的例子,在h2So4酸水解中不存在hcl水解的5种降解产物中的2种.本研究为修订压力试验以测
Doi:10.1002/jms.3533
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2907210001-间苯二酚
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-8835627-B2
优先权日:2012-03-27
标 题 :Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
发明人：LE FLOHIC ALEXANDRE; GRANDJEAN MATHIEU
权利人:SERVIER LAB
摘要:Process for the synthesis of ivabradine of formula (I): n nand addition salts thereof with a pharmaceutically acceptable acid.
专利号:MD-4468-C1
优先权日:2012-03-27
标 题 :The method of synthesis of ivabradine and its additive salts with pharmaceutically acceptable acids by lactation
专利号:US-2013261298-A1
优先权日:2012-03-27
标题:Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
专利号:NZ-608253-A
优先权日:2012-03-27
标 题:New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
专利号:DK-2644597-T3
优先权日:2012-03-27
标 题:NOVEL METHOD FOR SYNTHESIS OF ivabradine and addition salts with a pharmaceutically acceptable ACID
